Trials / Completed
CompletedNCT04874974
Feasibility of a Novel Process-based Treatment for Patients With Psychosis
The PROBAS-Study: Developing a Process-based and Modular Group Therapy for Acute Psychiatric Patients With Psychotic Symptoms: a Single-arm Feasibility Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Max-Planck-Institute of Psychiatry · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this single-arm feasibility study is to develop and pilot test a novel process-based and modular group therapy approach for patients with acute psychotic symptoms in an inpatient setting.
Detailed description
Due to the enormous economic and social costs of psychotic-spectrum disorders, increasing the effectiveness of treatment options has become an important subject for psychiatric research. Latest findings in the field of psychotherapy for psychosis show some promising results for so-called Process-based Therapies (PBT) such as the Metacognitive Training (MCT) and Acceptance and Commitment Therapy (ACT) (Barnicot et al., 2020). Instead of trying to change the content of psychotic symptoms such as hallucinations and delusions, PBT directly address cognitive processes, which have been found to maintain the disorder's symptomatology (Hayes et al., 2020). While MCT focusses on changing patients' cognitive biases by inducing metacognition (Moritz \& Woodward, 2007), ACT works with psychological processes such as mindfulness, willingness and cognitive distancing (Gaudiano \& Herbert, 2006). There is a growing study base for PBT in a psychotic outpatient setting, research in non-ambulatory settings though is rare (Barnicot et al., 2020). Therefore, the aim of the current study is to develop and test the feasibility and safety of a new process-based group therapy program for acute psychotic patients. The five-week treatment approach will consist of three different modules combining interventions from both MCT and ACT (Module I: Psychoeducation, Module II: Metacognition, Module III: Cognitive Defusion). First preliminary effectiveness and process measures (PANSS, BPRS, WHO-DAS, CGI, BCIS and CFQ) will also be included in order to inform the design of future research. Thus, the study will give valuables insights in the feasibility and effectiveness of an innovative psychotherapy approach and breaks new ground in the field of psychotherapy research for psychosis.
Conditions
- Schizophrenia
- Schizotypal Disorder
- Delusional Disorder
- Brief Psychotic Disorder
- Shared Psychotic Disorder
- Schizoaffective Disorder
- Other Psychotic Disorder Not Due to A Substance or Known Physiological Condition
- Unspecified Psychosis Not Due to a Substance or Known Physiological Condition
- Manic Episode, Severe With Psychotic Symptoms
- Bipolar Disorder, Current Episode Manic Severe With Psychotic Features
- Bipolar Disorder, Current Episode Depressed, Severe, With Psychotic Features
- Major Depressive Disorder, Single Episode, Severe With Psychotic Features
- Major Depressive Disorder, Recurrent, Severe With Psychotic Symptoms
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Metacognitive and Defusion Training | Module I will give a brief introduction into the rational of the therapy and explain the terms cognitive biases and relational responding and their role in the development of psychological problems (psychosis) in a simple language and with the help of examples and small exercises. The principle of metacognition and cognitive defusion in psychotherapy will be made clear. An outlook on the procedures and the goals of the group therapy will be given. Module II will include interventions adapted from the MCT manual (Moritz et al., 2017) and Module III with consist of defusion strategies taken from the ACT group manual (Dambacher et al., 2020) and existing studies on ACT and psychosis (Bach et al., 2013; Gaudiano \& Herbert, 2006). |
Timeline
- Start date
- 2021-05-10
- Primary completion
- 2022-03-10
- Completion
- 2023-09-23
- First posted
- 2021-05-06
- Last updated
- 2023-10-23
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT04874974. Inclusion in this directory is not an endorsement.